HOME >> BIOLOGY >> NEWS
UNC-CH bus brings mobile lab, high-tech science focus to underserved N.C. schools

as an ongoing resource for students, teachers and their schools and districts," he said. "The project will explore how universities and schools can best collaborate to contribute to science education reform in North Carolina. The support and interest from Glaxo Wellcome and its scientists will greatly advance our exploration."

The traveling science laboratory, which was built on a BlueBird chassis customized by Ohio Bus Specialty Vehicles in Canton, Ohio, will provide students and teachers access to equipment and instruction with a minimum of movement. Equipment inside includes wireless Internet access via satellite, laptop computers donated by IBM Corp., gel electrophoresis apparatus for separating proteins and DNA, a thermocycler for polymerase chain reaction experiments and incubators. Other items include spectrophotometers for finding the quantity of protein in a solution, a special plate reader to determine the concentration of a protein and a remotely controlled camera that enables students to see a teacher's demonstration on video monitors throughout the bus.

Program activities include a cutting-edge biomolecular science curriculum and inquiry-based, hands-on experiments developed by the Boston University School of Medicine's CityLab that include modules such as "The Case of the Crown Jewels," a DNA fingerprinting exercise, or "The Mystery of the Crooked Cell," which involves determining if a hypothetical patient has sickle cell anemia.

Local business and educational leaders will be invited to participate in activities during bus stops, which are expected to span several days at each site, Bollenbacher said.

The project will tap partners working to advance science education in North Carolina, he said. For example, the involvement of LEARN North Carolina, a one-stop Web site offered free to all N.C. public school systems through UNC-CH's School of Education, should broaden awareness of the variety of excellent programs at UNC-CH and elsewhere
'"/>

Contact: Mike McFarland
mike_mcfarland@unc.edu
919-962-8593
University of North Carolina at Chapel Hill
5-Apr-2000


Page: 1 2 3 4

Related biology news :

1. UNC-CH study indicates special vaccines could prevent insulin-dependent diabetes
2. Feds give $16 million to UNC-CH scientists studying waste site problems
3. UNC-CH study offers new evidence that garlic protects against cancers
4. UNC-CH researchers to study social effects of N.C. hurricane
5. UNC-CH experiments reveal new pen can disinfect water
6. UNC-CH researchers to comb N.C. mountains for iron problem chiefly affecting Scots, Irish
7. UNC-CH biologists identify new order of marine fungi
8. UNC-CH scientists create worlds smallest pieces of ice
9. UNC-CH scientist finds smallest number of genes needed for organisms survival
10. UNC-CH scientist encourages all to watch PBS series on microbes
11. Prestigious new nutrition research center being established at UNC-CH with NIH funding

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UNC bus brings mobile lab high tech science focus underserved schools

(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: